Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death
Cabazitaxel has been used to treat castration-resistant prostate cancer since its approval by the US Food and Drug Administration in 2010. However, whether cabazitaxel may inhibit the proliferation of other tissue-derived cancer cells, and its underlying mechanism, remains unknown. In the present st...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042750/ |